-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bristol Myers Squibb announced today that the European Medicines Management Agency (EMA) Committee for Medicinal human use (CHMP) has recommended approval of the Opdivo® (nivolumab) and Cabometyx® (cabozantinib) in combination with first-line treatment of advanced renal cell carcinoma (RCC).
management
Dana Walker, head of Bristol Myers Squibb's Genitourinary Cancer Development Program, said: "In recent years, the field of renal cell carcinoma treatment has undergone changes, and many advances have helped improve the prognosis of patients.
The positive opinion of CHMP comes from the positive results of the CheckMate-9ER Phase III trial.
The progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) of patients in the sunitinib Opdivo (nivolumab) combined with Cabometyx (cabozantinib) group were significantly improved.
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here